Table 2.
Clinical variables and PBSC graft cell subset doses tested in univariate analysis
| Variables* | Cumulative incidence of grade II-IV aGVHD, % (95% CI) | P |
|---|---|---|
| TBI | .26 | |
| TBI/Cy (n = 39) | 51 (34-66) | |
| Non-TBI (n = 18) | 39 (16-61) | |
| Recipient age | .91 | |
| < 47.2 y | 46 (27-63) | |
| ≥ 47.2 y | 48 (29-65) | |
| Donor age | .85 | |
| < 47.5 y | 46 (27-64) | |
| ≥ 47.5 y | 48 (29-65) | |
| Sex mismatch | .46 | |
| Yes (n = 19) | 50 (33-65) | |
| No (n = 38) | 42 (20-63) | |
| Disease risk† | .74 | |
| Standard (n = 16) | 44 (19-66) | |
| High (n = 41) | 49 (36-63) | |
| Conditioning | .53 | |
| Myeloablative (n = 41) | 44 (19-67) | |
| RIC (n = 16) | 49 (33-63) | |
| Diagnosis | .038 | |
| CML (n = 18) | 61 (34-80) | |
| Other (n = 39) | 41 (25-56) | |
| CD34+ cells | .52 | |
| < 5.66 × 106 cells/kg of body weight | 54 (33-70) | |
| ≥ 5.66 × 106 cells/kg of body weight | 41 (23-59) | |
| NK cells | .28 | |
| < 11.7 × 106 cells/kg of body weight | 39 (21-57) | |
| ≥ 11.7 × 106 cells/kg of body weight | 55 (35-71) | |
| B cells | .12 | |
| < 33.5 × 106 cells/kg of body weight | 57 (36-73) | |
| ≥ 33.5 × 106 cells/kg of body weight | 38 (20-55) | |
| T cells | .24 | |
| < 154 × 106 cells/kg of body weight | 54 (32-70) | |
| ≥ 154 × 106 cells/kg of body weight | 41 (23-58) | |
| CD4+ T cells | .71 | |
| < 91.2 × 106 cells/kg of body weight | 46 (27-64) | |
| ≥ 91.2 × 106 cells/kg of body weight | 48 (29-65) | |
| CD8+ T cells | .09 | |
| < 40.3 × 106 cells/kg of body weight | 57 (36-73) | |
| ≥ 40.3 × 106 cells/kg of body weight | 38 (20-55) | |
| Tregs | .6 | |
| < 4.9 × 106 cells/kg of body weight | 50 (30-67) | |
| ≥ 4.9 × 106 cells/kg of body weight | 45 (26-61) | |
| CD3+CD161+ cells | .62 | |
| < 7.07 × 106 cells/kg of body weight | 46 (27-64) | |
| ≥ 7.07 × 106 cells/kg of body weight | 48 (28-65) | |
| iNKT cells | .014 | |
| < 0.057 × 106 cells/kg of body weight | 64 (43-79) | |
| ≥ 0.057 × 106 cells/kg of body weight | 31 (15-48) | |
| CD4+ iNKT cells | .002 | |
| < 0.026 × 106 cells/kg of body weight | 68 (46-82) | |
| ≥ 0.026 × 106 cells/kg of body weight | 26 (13-45) | |
| CD4− iNKT cells | .0008 | |
| < 0.031 × 106 cells/kg of body weight | 71 (50-85) | |
| ≥ 0.031 × 106 cells/kg of body weight | 24 (10-41) |
TBI indicates total body irradiation; Cyclo, cyclophosphamide; and RIC, reduced intensity conditioning.
*
Median values are shown.
†
Standard risk indicates CML chronic phase 1, acute myeloid leukemia/acute lymphoblastic leukemia standard risk in first complete remission; and high risk, all other.